InsiderTrades.com logo
Juan Sanchez net worth and biography
  • LinkedIn
  • Phone
  • Website

Juan Sanchez Biography and Net Worth

Director of Nuvectis Pharma

Dr. Sanchez joined our Board of Directors in September 2025. Dr. Sanchez brings 30+ years of multifaceted experience that uniquely integrates key healthcare perspectives including direct patient care as a medical doctor, research analysis on Wall Street followed by serving as a leading executive at a prominent biopharmaceutical company, Intra-Cellular Therapies. Dr. Sanchez joined Intra-Cellular Therapies in 2014 and his tenure spanned the successful clinical development and commercialization of CAPLYTA (lumateperone), culminating in the company’s acquisition by Johnson & Johnson in April 2025 for $14.6 billion. Prior to that, Dr. Sanchez was a managing director of healthcare equity research at Ladenburg Thalmann & Co. and Punk, Ziegel & Co. Dr. Sanchez holds a Master’s degree in International Affairs from Columbia University in New York, an MBA from the University of Los Andes in Columbia and received his Doctor of Medicine degree from Pontifical Xavierian University in Bogota, Columbia. Dr. Sanchez practiced medicine for 5 years in Colombia.

What is Juan Sanchez's net worth?

The estimated net worth of Juan Sanchez is at least $790.49 thousand as of November 5th, 2025. Sanchez owns 78,150 shares of Nuvectis Pharma stock worth more than $790,487 as of May 7th. This net worth evaluation does not reflect any other investments that Sanchez may own. Learn More about Juan Sanchez's net worth.

How do I contact Juan Sanchez?

The corporate mailing address for Sanchez and other Nuvectis Pharma executives is , , . Nuvectis Pharma can also be reached via phone at 201-614-3150. Learn More on Juan Sanchez's contact information.

Has Juan Sanchez been buying or selling shares of Nuvectis Pharma?

Juan Sanchez has not been actively trading shares of Nuvectis Pharma over the course of the past ninety days. Most recently, on Wednesday, November 5th, Juan Sanchez bought 13,000 shares of Nuvectis Pharma stock. The stock was acquired at an average cost of $5.79 per share, with a total value of $75,270.00. Following the completion of the transaction, the director now directly owns 78,150 shares of the company's stock, valued at $452,488.50. Learn More on Juan Sanchez's trading history.

Who are Nuvectis Pharma's active insiders?

Nuvectis Pharma's insider roster includes Enrique Poradosu (Insider), and Juan Sanchez (Director). Learn More on Nuvectis Pharma's active insiders.

Are insiders buying or selling shares of Nuvectis Pharma?

In the last year, Nuvectis Pharma insiders bought shares 11 times. They purchased a total of 246,632 shares worth more than $1,634,080.06. The most recent insider tranaction occured on November, 5th when CEO Ron Bentsur bought 5,000 shares worth more than $28,600.00. Insiders at Nuvectis Pharma own 30.5% of the company. Learn More about insider trades at Nuvectis Pharma.

Information on this page was last updated on 11/5/2025.

Juan Sanchez Insider Trading History at Nuvectis Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/5/2025Buy13,000$5.79$75,270.0078,150View SEC Filing Icon  
See Full Table

Juan Sanchez Buying and Selling Activity at Nuvectis Pharma

This chart shows Juan Sanchez's buying and selling at Nuvectis Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nuvectis Pharma Company Overview

Nuvectis Pharma logo
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Read More

Today's Range

Now: $9.91
Low: $9.85
High: $10.49

50 Day Range

MA: $8.53
Low: $7.48
High: $10.00

2 Week Range

Now: $9.91
Low: $5.55
High: $11.15

Volume

61,389 shs

Average Volume

63,327 shs

Market Capitalization

$274.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A